Compare Baker Hughes Co (BKR) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baker Hughes Co vs Zoetis Inc — how do they compare? Baker Hughes Co trades at $64.77 (market cap $64.34B), while Zoetis Inc trades at $72.52 (market cap $31.14B). The key difference: Baker Hughes Co is far larger — about 2.1× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| BKR | ZTS | |
|---|---|---|
Market Cap | $64.34B | $31.14B |
Sector | Energy | Health |
52-Week High | $69.67 | $156.76 |
52-Week Low | $42.51 | $71.91 |
Enterprise Value | $64.86B | $38.70B |
Dividend Yield | 1.42% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baker Hughes (BKR) trades at $64.07, up 4.09% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.64 exceeding expectations. Recent contract wins in subsea systems and LNG technology, along with the Chart Industries acquisition, position the company for growth despite modest oil & gas spending headwinds. Operating cash flow reached $3.81 billion in 2025, supporting financial stability.
BKR presents a favorable risk-reward profile with 66.7% analyst buy ratings and a $73.25 consensus target offering 14% upside. Key risks include integration challenges from acquisitions and oil market volatility, but strong backlog and margin expansion support the bullish case. The stock remains attractive for investors seeking energy technology exposure with solid cash flow generation.
Zoetis (ZTS) trades at $74.86, up 3.03% today but facing bearish technical signals with 16 sell indicators. The company reported mixed Q2 2026 results, beating EPS estimates but missing revenue expectations, while cutting full-year guidance due to softer pet healthcare demand. Strong fundamentals include a 27.69% net margin and 64.91% ROE, though valuation metrics show a P/E of 12.29 and P/S of 3.41.
The stock presents a value opportunity with analyst consensus target of $94.90 (27% upside), but faces near-term headwinds from competitive pressures and class action lawsuits. Investors should weigh strong profitability against slowing growth in companion animal segments and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
